Accrufer Shortage: What Providers and Prescribers Need to Know in 2026

As a healthcare provider, you may have heard from patients that they can't find Accrufer (Ferric Maltol) at their pharmacy. While Accrufer is not currently listed on the FDA drug shortage database, its status as a single-source brand-name oral iron therapy creates persistent access challenges that are worth understanding.

This briefing covers the current supply landscape, prescribing implications, cost considerations, and tools you can share with patients to improve access.

Product Overview

Accrufer (Ferric Maltol) is a non-salt-based oral iron replacement therapy manufactured by Shield Therapeutics. Key prescribing details:

• FDA approval: Originally approved July 2019 for iron deficiency in adults. Expanded in early 2026 to include patients aged 10 years and older.
• Dosage: 30 mg oral capsule, taken twice daily on an empty stomach (1 hour before or 2 hours after meals)
• Treatment duration: Typically 12 weeks; continue until ferritin levels normalize
• Mechanism: Ferric iron complexed with maltol delivers iron with reduced free iron release in the GI tract, resulting in improved tolerability compared to ferrous salts

For detailed pharmacology, see our article on Accrufer's mechanism of action.

Supply and Availability Timeline

Understanding Accrufer's availability history helps contextualize current patient complaints:

• 2019: FDA approval granted; initial U.S. commercial launch
• 2020–2023: Gradual adoption; limited formulary placement
• 2024–2025: Increasing prescriber awareness; patient reports of difficulty finding stock at retail pharmacies
• Early 2026: Pediatric approval (ages 10+); e-pharmacy option available; copay savings program continues
• Current status: Not on FDA shortage list. Supply is available from the manufacturer, but retail pharmacy stocking remains inconsistent.

Prescribing Implications

Prior Authorization and Step Therapy

Most commercial payers require prior authorization for Accrufer. Many also enforce step therapy, requiring documented failure of or intolerance to Ferrous Sulfate before approving coverage. When submitting prior authorization:

• Document previous oral iron trials (drug name, dose, duration, reason for discontinuation)
• Include relevant lab values (ferritin, TIBC, hemoglobin)
• Note clinical rationale — GI intolerance, IBD, malabsorption, or other factors

Drug Interactions

Ferric Maltol has clinically significant interactions that affect prescribing decisions:

• Eltrombopag: Contraindicated — ferric maltol inhibits GI absorption
• Dimercaprol: Avoid concomitant use
• Doxycycline and other tetracyclines: Separate by at least 4 hours
• All oral medications: Recommend patients take Accrufer 4 hours before or after other oral drugs
• Levothyroxine, quinolones, bisphosphonates: Standard iron-drug interaction precautions apply

A comprehensive list is available in our Accrufer drug interactions guide.

Current Availability Picture

The "shortage" patients report is primarily a stocking and distribution issue, not a manufacturing one:

• Retail chains (CVS, Walgreens, Rite Aid): Frequently do not carry Accrufer as a standard inventory item. Can order within 1–2 business days.
• Independent pharmacies: Often more willing to stock or quickly order specialty brands.
• Specialty pharmacies: Most reliable for immediate availability.
• E-pharmacy: Shield Therapeutics offers direct-to-patient shipping via accrufer.com.

When patients report inability to find Accrufer, it's worth verifying whether the barrier is stock, insurance, or cost — as each has a different solution.

Cost and Access Considerations

Cost remains a significant barrier for many patients:

• Average retail price: $610–$710 for 60 capsules (30-day supply)
• With GoodRx coupon: ~$199
• Copay savings card: Eligible commercially insured patients may pay $0 (not valid for Medicare/Medicaid)
• No generic available: Patent protections expected to last until ~2035

For patients who are uninsured or underinsured, Shield Therapeutics offers a patient support program. NeedyMeds and RxAssist may list additional assistance options.

Provider-focused cost information is also available in our guide on helping patients save money on Accrufer.

Tools and Resources for Your Practice

Several tools can help your patients locate and access Accrufer:

• Medfinder for Providers: medfinder.com/providers — real-time pharmacy stock lookup that you can use during patient encounters or share with your team
• Accrufer Copay Card: accrufer.copaysavingsprogram.com — print or digital copay assistance
• Accrufer HCP Site: accruferhcp.com — clinical data, PI, and prescribing resources
• Patient education materials: Share our patient-facing articles on finding Accrufer in stock and what to expect with side effects

Clinical Alternatives When Accrufer Is Unavailable

When patients cannot access Accrufer, consider these alternatives based on clinical context:

• Ferrous Sulfate 325 mg: First-line for cost-sensitive patients without GI intolerance. Every-other-day dosing may improve tolerability.
• Ferrous Gluconate 324 mg: Lower elemental iron per dose; may be better tolerated.
• Injectafer (Ferric Carboxymaltose): IV iron for patients who have failed oral therapy. Two-dose regimen (750 mg each, one week apart).
• Venofer (Iron Sucrose): IV iron particularly appropriate for CKD patients. Requires more infusion visits.

Detailed comparisons are available in our alternatives to Accrufer guide.

Looking Ahead

Several factors may improve Accrufer access in the coming years:

• Growing prescriber awareness and formulary adoption may drive increased pharmacy stocking
• The pediatric approval expands the eligible patient population, which could increase demand and pharmacy inventory
• Shield Therapeutics continues to expand distribution channels and e-pharmacy capabilities
• Generic entry is not expected until approximately 2035, so brand-name access strategies will remain important for the foreseeable future

Final Thoughts

Accrufer fills an important clinical niche as a well-tolerated oral iron option for patients who struggle with traditional ferrous salts. While access is not always straightforward, the barriers are manageable with the right tools and patient education.

We recommend directing patients to Medfinder for Providers and proactively assisting with prior authorization to minimize treatment delays. For a practical workflow guide, see our article on how to help your patients find Accrufer in stock.